We Think ALTEOGEN (KOSDAQ:196170) Can Stay On Top Of Its Debt
Feb 14
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Biotech Industry Analysis
UpdatedFeb 17, 2026
DataAggregated Company Financials
Companies123
- 7D1.6%
- 3M8.3%
- 1Y42.6%
- YTD1.7%
In the last week, the Biotech industry is up 5.7%, with Celltrion up 8.2%. In the same time, Kolon TissueGene was down 5.1%. This takes the industry's 12 month performance to a gain of 45%. As for the next few years, earnings are expected to grow by 42% per annum.
Industry Valuation and Performance
Has the South Korean Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 17 Feb 2026 | ₩171.9t | ₩13.1t | ₩199.9b | 23.7x | 859.9x | 13.1x |
| Thu, 15 Jan 2026 | ₩168.0t | ₩13.1t | ₩224.5b | 24x | 748.6x | 12.8x |
| Sat, 13 Dec 2025 | ₩160.7t | ₩13.1t | ₩274.1b | 27.1x | 586.3x | 12.3x |
| Mon, 10 Nov 2025 | ₩127.3t | ₩12.4t | -₩26,946,125,353.00 | 25.6x | -4723.6x | 10.2x |
| Wed, 08 Oct 2025 | ₩122.3t | ₩12.4t | -₩30,278,124,823.00 | 28.1x | -4039.2x | 9.8x |
| Fri, 05 Sep 2025 | ₩117.7t | ₩12.4t | -₩90,407,978,835.00 | 28.7x | -1301.8x | 9.5x |
| Sun, 03 Aug 2025 | ₩108.9t | ₩11.8t | -₩227,694,607,523.00 | 22.6x | -478.1x | 9.2x |
| Tue, 01 Jul 2025 | ₩103.7t | ₩11.9t | -₩217,112,016,353.00 | 25.5x | -477.7x | 8.7x |
| Thu, 29 May 2025 | ₩97.7t | ₩11.7t | -₩240,935,759,255.00 | 28.1x | -405.3x | 8.3x |
| Sat, 26 Apr 2025 | ₩97.6t | ₩11.4t | -₩456,504,996,975.00 | 28.1x | -213.8x | 8.6x |
| Mon, 24 Mar 2025 | ₩100.5t | ₩11.5t | -₩757,294,802,150.00 | 32.8x | -132.8x | 8.8x |
| Wed, 19 Feb 2025 | ₩100.6t | ₩10.6t | -₩910,887,650,061.00 | 23.7x | -110.4x | 9.5x |
| Fri, 17 Jan 2025 | ₩93.1t | ₩10.5t | -₩1,004,347,149,181.00 | 24.5x | -92.7x | 8.9x |
| Sun, 15 Dec 2024 | ₩94.2t | ₩10.5t | -₩1,002,002,014,281.00 | 23.9x | -94x | 9x |
| Tue, 12 Nov 2024 | ₩97.2t | ₩10.3t | -₩650,692,798,177.00 | 26.6x | -149.4x | 9.4x |
| Thu, 10 Oct 2024 | ₩95.4t | ₩10.3t | -₩653,791,712,887.00 | 25.4x | -145.9x | 9.2x |
| Sat, 07 Sep 2024 | ₩89.1t | ₩10.3t | -₩664,461,088,267.00 | 24.1x | -134x | 8.6x |
| Mon, 05 Aug 2024 | ₩90.3t | ₩9.9t | -₩651,620,427,048.00 | 22.7x | -138.6x | 9.2x |
| Wed, 03 Jul 2024 | ₩84.0t | ₩9.9t | -₩651,620,427,048.00 | 22.1x | -128.9x | 8.5x |
| Fri, 31 May 2024 | ₩78.1t | ₩9.9t | -₩643,765,772,388.00 | 20.5x | -121.4x | 7.9x |
| Sun, 28 Apr 2024 | ₩78.6t | ₩9.6t | -₩574,854,220,678.00 | 21.8x | -136.7x | 8.2x |
| Tue, 26 Mar 2024 | ₩85.8t | ₩9.6t | -₩603,302,771,467.00 | 45.5x | -142.2x | 9x |
| Thu, 22 Feb 2024 | ₩74.5t | ₩9.7t | -₩534,696,541,747.00 | 61.7x | -139.3x | 7.6x |
| Sat, 20 Jan 2024 | ₩72.8t | ₩9.7t | -₩537,261,689,777.00 | 61.3x | -135.5x | 7.5x |
| Mon, 18 Dec 2023 | ₩58.9t | ₩10.1t | -₩311,749,314,637.00 | 28.3x | -188.8x | 5.8x |
| Wed, 15 Nov 2023 | ₩55.4t | ₩10.2t | -₩233,197,853,989.00 | 30.6x | -237.4x | 5.4x |
| Fri, 13 Oct 2023 | ₩55.7t | ₩10.2t | -₩239,053,318,689.00 | 28.1x | -233.2x | 5.5x |
| Sun, 10 Sep 2023 | ₩58.8t | ₩10.2t | -₩340,060,706,949.00 | 34x | -172.9x | 5.8x |
| Tue, 08 Aug 2023 | ₩57.8t | ₩10.3t | -₩151,534,704,579.00 | 28.8x | -381.4x | 5.6x |
| Thu, 06 Jul 2023 | ₩57.3t | ₩10.3t | -₩151,534,704,579.00 | 27.5x | -378.1x | 5.6x |
| Sat, 03 Jun 2023 | ₩64.1t | ₩10.3t | -₩151,338,675,579.00 | 32.2x | -423.5x | 6.2x |
| Mon, 01 May 2023 | ₩60.0t | ₩11.0t | ₩317.9b | 24.4x | 188.8x | 5.5x |
| Wed, 29 Mar 2023 | ₩56.5t | ₩10.8t | ₩436.1b | 23.4x | 129.5x | 5.2x |
| Fri, 24 Feb 2023 | ₩57.8t | ₩11.3t | ₩968.6b | 25.4x | 59.6x | 5.1x |
Price to Earnings Ratio
59.6x
Current Industry PE
- Investors are optimistic on the South Korean Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 860x which is higher than its 3-year average PE of -458x.
- The 3-year average PS ratio of 8.2x is lower than the industry's current PS ratio of 13.1x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have declined 41% per year over the last three years.
- Meanwhile revenues for these companies have grown 5.1% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare industry?
| KR Market | 3.37% | |
| Healthcare | 0.66% | |
| Biotech | 1.61% | |
| Biotech | 1.61% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A068270 Celltrion | ₩238.00k | 4.6% +₩2.3t | 37.3% | PE70.6x | |
| A397030 AprilBioLtd | ₩65.40k | 22.7% +₩282.4b | 258.7% | PS170.1x | |
| A196170 ALTEOGEN | ₩382.00k | 1.1% +₩213.9b | -3.3% | PE162.2x | |
| A347850 D&D Pharmatech | ₩83.50k | 5.4% +₩187.2b | 523.1% | PS434.7x | |
| A290650 L&C BIOLTD | ₩95.90k | 6.3% +₩141.6b | 350.2% | PE30.3x |
